^
Association details:
| Biomarker: | KRAS mutation + STK11 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Diminished efficacy of PD-(L)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is impacted by KRAS mutation status
Published date:
11/02/2021
Excerpt:
In each independent cohort, as well as in the combined cohort, STK11 and KEAP1 mutations were associated with significantly worse progression-free (STK11 HR: 2.04, P<0.0001; KEAP1 HR 2.05, P<0.0001), and overall survival (STK11 HR: 2.09 ,P<0.0001; KEAP1 HR 2.24, P<0.0001) to immunotherapy uniquely among KRAS MUT but not KRAS WT LUADs.
DOI:
10.1016/j.jtho.2021.10.013
